Gilead Sciences signed a contract with four Indian pharmaceutical companies to produce its medication ‘Remdesivir’ which has been found effective in treatment of some COVID-19 patients.
Lupin and Aurobindo Pharma have been recommended for hold by research house Prabhudas Lilladher. Target price for Aurobindo Pharma has been suggested Rs 511.